CLASS II Drug recall · Reported 22 May 2013 · FDA Enforcement Report
Lidocaine Injection, all strengths recalled by FVS Holdings
FVS Holdings is recalling Lidocaine Injection, all strengths and all presentations including a) Lidocaine _HCl-0.5%, distributed nationwide in the US. The recall was initiated on 10 Apr 2013 and the FDA has classified it as Class II.
Check your package
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
Recall details
- Recall number
- D-379-2013
- FDA event ID
- 64879
- Recalling firm
- FVS Holdings, Henderson, NV
- Classification
- Class II
- Status
- Terminated
- Recall initiated
- 10 Apr 2013
- FDA classified
- 16 May 2013
- Reported
- 22 May 2013
- Type
- Voluntary: Firm initiated
- Customers notified by
- Press Release
- Reason category
- Sterility
- Drug class
- Pain Medication
Timeline
| 10 Apr 2013 | Recall initiated by company | |
| 16 May 2013 | Classified by FDA | +36 days |
| 22 May 2013 | Published in enforcement report | +6 days |
Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.
Reason for recall
Lack of Assurance of Sterility: all sterile products compounded, repackaged, and distributed by this compounding pharmacy due to lack of sterility assurance and concerns associated with the quality control processes.
A sterility recall means a product that must be sterile, such as an injection or eye drop, may be contaminated. Using a non-sterile product can cause serious infection.
Product as listed by the FDA
Lidocaine Injection, all strengths and all presentations including a) Lidocaine _HCl-0.5%, b) Lidocaine HCl, c) Lidocaine 1%, d) Lidocaine 1% 50 mL, e) Lidocaine 2 %, f) Lidocaine 2% 50 mL, g) Lidocaine 2% 50 mL MDV, Rx only, Green Valley Drugs, 1850 Whitney Mesa, #180, Henderson, NV 89014.
Where it was distributed
Nationwide
Questions about this recall
Why was it recalled?
Lack of Assurance of Sterility: all sterile products compounded, repackaged, and distributed by this compounding pharmacy due to lack of sterility assurance and concerns associated with the quality control processes.
Which lots are affected?
Lot #: a) Lidocaine _HCl-0.5%: 20130403-J, 20130403-F, 20130403-H, 20130403-G, 20130403-I, Exp 7/3/2013; 2013117-I, Exp 4/17/2013; b) Lidocaine HCl: 20130131-H, Exp 4/30/2013; c) Lidocaine 1%: 20130204-N, Exp 5/4/2013; 20130115-A, Exp 4/15/2013; 20130128-E, Exp 4/28/2013; 20130220-G, Exp 5/20/2013; 20130221-J, Exp 5/21/2013; 20130221-K, Exp 5/21/2013; 20130204-J, Exp 5/4/2013; 20130315-J, Exp 6/15/2013; 20130315-K, Exp 6/15/2013; 20130328-E, Exp 6/28/2013; 20130328-H, Exp 6/28/2013; 20130328-I, Exp 6/28/2013; 20130328-K, Exp 6/28/2013; 20130329-B, Exp 6/29/2013; 20130329-C, Exp 6/29/2013; 20130304-K, Exp 6/4/2013; 20130304-L, Exp 6/4/2013; 20130305-L, Exp 6/5/2013; 20130305-D, Exp 6/5/2013; 20130306-H, Exp 6/6/2013; 20130306-P, Exp 6/6/2013; 20130307-J, Exp 6/7/2013; 20130115-B, Exp 4/15/2013; 20130201-M, Exp 5/1/2013; 20130214-A, Exp 5/14/2013; 20130204-M, Exp 5/4/2013; 20130328-F, Exp 6/28/2013; 20130329-A, Exp 6/29/2013; 20130305-M, Exp 6/5/2013; 20130305-D, Exp 6/5/2013; 20130328-J, Exp 6/28/2013; d) Lidocaine 1% 50 ml: 20130128-D, 4/28/2013; 20130115-D, Exp 4/15/2013; 20130115-F, Exp 4/15/2013; 20130117-H, Exp 4/17/2013; 20130115-C, Exp 4/15/2013; e) Lidocaine 2 %: 20130325-F, Exp 6/25/2013; 20130130-N, Exp 4/30/2013; 20130221-L, Exp 5/21/2013; 20130221-N, Exp 5/21/2013; 20130228-I, Exp 5/28/2013; 20130314-H, Exp 6/14/2013; 20130314-I, Exp 6/14/2013; 20130315-E, Exp 6/15/2013; 20130315-F, Exp 6/15/2013; 20130318-K, Exp 6/18/2013; 20130320-D, Exp 6/20/2013; 20130320-B, Exp 6/20/2013; 0130328-D, Exp 6/28/2013; 20130328-G, Exp 6/28/2013; 20130305-E, Exp 6/5/2013; 20130130-M, Exp 4/30/2013; 20130221-M, Exp 5/21/2013; 20130221-O, Exp 5/21/2013; 20130325-E, Exp 6/25/2013; f) Lidocaine 2% 50ml: 20130320-C, Exp 6/20/2013; 20130305-F, Exp 6/5/2013; 20130305-I, Exp 6/5/2013; 20130301-A, Exp 6/1/2013; 20130304-L, Exp 6/4/2013; g) Lidocaine 2% 50ml MDV: 20130227-E, Exp 5/27/2013
Where was it sold?
Nationwide
What should I do if I have it?
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
What does Class II mean?
Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.
Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.
Other products in this recall event
77 other products · FDA event 64879This product is part of a recall event; the main page for the event is Medroxyprogesterone Acetate Injection, all strengths recalled.
More recalls from FVS Holdings
All 78| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Sodium Bicarbonate Injection, all strengths recalled by FVS Holdings | FVS Holdings | Sterility | Nationwide |
| Drug | CLASS II | Progesterone Injection, all strengths recalled by FVS Holdings | FVS Holdings | Sterility | Nationwide |
| Drug | CLASS II | Polidocanol Injection, all strengths recalled by FVS Holdings | FVS Holdings | Sterility | Nationwide |
| Drug | CLASS II | Hydroxocobalamin Injection, all strengths recalled by FVS Holdings | FVS Holdings | Sterility | Nationwide |
| Drug | CLASS II | Hydrogen Peroxide Injection, all strengths recalled by FVS Holdings | FVS Holdings | Sterility | Nationwide |
Other Lidocaine recalls
All 119| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Xylocaine (lidocaine HCl Injection, USP), 1%, 500 mg recalledXylocaine | Fresenius Kabi USA | Particulate Matter | Nationwide |
| Drug | CLASS III | Lidolog Kit, Kit Contains: Lidocaine HCl Injection recalledLidolog Kit | Asclemed USA | Other | TN |
| Drug | CLASS II | Lidocaine HCl Injection, USP, 2%, 100 mg recalled by Fresenius Kabi USALidocaine | Fresenius Kabi USA | Particulate Matter | Nationwide |
| Drug | CLASS II | Xylocaine (lidocaine HCl Injection, USP), 1%, 200 mg recalledXylocaine | Fresenius Kabi USA | Particulate Matter | Nationwide |
| Drug | CLASS II | Lidocaine HCl Injection USP, 1% (10 mg/mL) single dose ampule recalledLidocaine Hydrochloride | Asclemed USA | Sterility | Nationwide |